Description
PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10
First action · last action
2022-05-20 · 2022-05-20
Transactions
1
First transaction's obligation
$198,705
Base + all options value (sum of deltas)
$198,705
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
—
Offers received
1
SDVOSB flag on record
No
Parent IDV
36F79719D0224
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 1 transaction
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-05-20+$198,705= $198,705
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-05-20 | +$198,705 | $198,705 | PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI SK1UK7S74GB3)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24525N0427 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $76,897 | FY2025 |
| 36C24525N0296 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $76,897 | FY2025 |
| 36C24525N0224 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $37,269 | FY2025 |
| 36C24525N0145 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $37,269 | FY2025 |
| 36C24524N0929 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $55,903 | FY2024 |
| 36C24524N0914 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $55,903 | FY2024 |
Other recipients under 6505 from 260-NETWORK CONTRACT OFFICE 20 (36C260) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26026F0379 | COSETTE PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $3,466 | FY2026 |
| 36C26026P0671 | MCKESSON PLASMA AND BIOLOGICS LLC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $18,262 | FY2026 |
| 36C26026F0349 | AGIOS PHARMACEUTICALS, INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $73,080 | FY2026 |
| 36C26026F0306 | BRACCO DIAGNOSTICS INC. | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $337,422 | FY2026 |
| 36C26026F0298 | PROGENICS PHARMACEUTICALS INC | 260-NETWORK CONTRACT OFFICE 20 (36C260) | $469,134 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26022F0281_3600_36F79719D0224_3600 · retrieved 2026-09-26.